Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Update

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 21,880,000 shares, a growth of 39.6% from the November 30th total of 15,670,000 shares. Based on an average daily trading volume, of 4,270,000 shares, the days-to-cover ratio is currently 5.1 days.

Institutional Trading of Taysha Gene Therapies

A number of large investors have recently bought and sold shares of the stock. Creative Planning bought a new position in shares of Taysha Gene Therapies during the third quarter valued at $28,000. Principal Financial Group Inc. acquired a new position in Taysha Gene Therapies in the second quarter valued at about $48,000. China Universal Asset Management Co. Ltd. grew its stake in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth approximately $85,000. Finally, Scientech Research LLC bought a new position in shares of Taysha Gene Therapies in the second quarter valued at approximately $97,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Price Performance

NASDAQ TSHA traded down $0.11 during trading on Friday, reaching $1.75. 1,600,983 shares of the company traded hands, compared to its average volume of 2,845,679. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The company has a market cap of $358.65 million, a price-to-earnings ratio of 2.78 and a beta of 0.79. The stock’s 50 day moving average price is $2.12 and its two-hundred day moving average price is $2.24. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TSHA shares. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group raised their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus price target of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.